4P-Pharma and Oncocross, a Korea-based AI biotech, signed a research collaboration agreement at the Institut Pasteur de Lille on October 25th, 2021.
The two companies will join their expertise to bring an innovative therapeutic agent to the patients affected by Systemic Scleroderma, a rare autoimmune disease affecting the skin and internal organs that has no approved treatment in the market.
Dr. Yirang Kim, CEO of Oncocross, mentioned that “we are very excited about this collaboration with 4P-Pharma, […].”
Dr. Revital Rattenbach, chairwoman of 4P-Pharma said “This research collaboration agreement with Oncocross is an important opportunity to successfully develop an innovative therapy rapidly. […]”
Dr. Yirang Kim, CEO of Oncocross, and Dr. Revital Rattenbach, chairwoman of 4P-Pharma, celebrating the signature of a research collaboration agreement between Oncocross and 4P-Pharma in Lille (France).
Read the full press release:
EN: 20211104_PR_Oncocross-4P_EN
FR: 20211104_PR_Oncocross-4P_FR
KR: 20211104_PR_Oncocross-4P_KR
Press contact 4P-Pharma
Roselina Lam, Business Development and Licensing-in Manager
E-mail: roselina@4p-pharma.com